<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0034">
 <label>34.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Gruber</surname>
    <given-names>MF</given-names>
   </name>, 
   <name name-style="western">
    <surname>Farizo</surname>
    <given-names>KM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Pratt</surname>
    <given-names>RD</given-names>
   </name>, 
   <name name-style="western">
    <surname>Fink</surname>
    <given-names>DL</given-names>
   </name>, 
   <name name-style="western">
    <surname>Finn</surname>
    <given-names>TM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Krause</surname>
    <given-names>PR</given-names>
   </name>, 
   <name name-style="western">
    <surname>Borio</surname>
    <given-names>LL</given-names>
   </name>, 
   <name name-style="western">
    <surname>Marks</surname>
    <given-names>PW</given-names>
   </name>
  </person-group>
  <article-title>Clinical development strategies and considerations for zika vaccine licensure</article-title>. 
  <source>J Infect Dis</source>. 
  <year>2017</year>;
  <volume>216</volume>:
  <fpage>S964</fpage>â€“
  <lpage>S970</lpage>. doi:
  <pub-id pub-id-type="doi">10.1093/infdis/jix433</pub-id>.
  <pub-id pub-id-type="pmid">29267913</pub-id>
 </mixed-citation>
</ref>
